CA3245866A1 - BLOOD-BRAIN BARRIER CROSSING PROTEIN-PROTEIN INTERACTION INHIBITORS (MLL1-WDR5) AND THEIR USES - Google Patents

BLOOD-BRAIN BARRIER CROSSING PROTEIN-PROTEIN INTERACTION INHIBITORS (MLL1-WDR5) AND THEIR USES

Info

Publication number
CA3245866A1
CA3245866A1 CA3245866A CA3245866A CA3245866A1 CA 3245866 A1 CA3245866 A1 CA 3245866A1 CA 3245866 A CA3245866 A CA 3245866A CA 3245866 A CA3245866 A CA 3245866A CA 3245866 A1 CA3245866 A1 CA 3245866A1
Authority
CA
Canada
Prior art keywords
compound
formula
mouse
mpk
body weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3245866A
Other languages
English (en)
French (fr)
Inventor
Farbod Shojaei
Che Fang
J. Edward Semple
Mireille Gillings
Original Assignee
Huyabio International LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huyabio International LLC filed Critical Huyabio International LLC
Publication of CA3245866A1 publication Critical patent/CA3245866A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3245866A 2022-03-14 2023-03-10 BLOOD-BRAIN BARRIER CROSSING PROTEIN-PROTEIN INTERACTION INHIBITORS (MLL1-WDR5) AND THEIR USES Pending CA3245866A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263319589P 2022-03-14 2022-03-14
US63/319,589 2022-03-14
PCT/US2023/015021 WO2023177592A1 (en) 2022-03-14 2023-03-10 Blood-brain barrier crossing mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof

Publications (1)

Publication Number Publication Date
CA3245866A1 true CA3245866A1 (en) 2023-09-21

Family

ID=88024124

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3245866A Pending CA3245866A1 (en) 2022-03-14 2023-03-10 BLOOD-BRAIN BARRIER CROSSING PROTEIN-PROTEIN INTERACTION INHIBITORS (MLL1-WDR5) AND THEIR USES

Country Status (7)

Country Link
US (1) US20230293539A1 (https=)
EP (1) EP4493184A4 (https=)
JP (1) JP2025509830A (https=)
KR (1) KR20250009417A (https=)
CA (1) CA3245866A1 (https=)
MX (1) MX2024011346A (https=)
WO (1) WO2023177592A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025090881A1 (en) * 2023-10-27 2025-05-01 Huyabio International, Llc Combination therapies of wdr5 inhibitors and pd-1 inhibitors
WO2026058961A1 (en) 2024-09-13 2026-03-19 Alivexis, Inc. Wdr5 inhibitors, compounds, pharmaceutical compositions, and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063058B2 (en) * 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US11319299B2 (en) * 2016-03-01 2022-05-03 Propellon Therapeutics Inc. Substituted carboxamides as inhibitors of WDR5 protein-protein binding
CN107382840B (zh) * 2016-05-16 2020-09-01 四川大学 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途
WO2019046944A1 (en) * 2017-09-06 2019-03-14 Propellon Therapeutics Inc. INHIBITORS OF PROTEIN BINDING WDR5-PROTEIN
CN108715585A (zh) * 2018-04-23 2018-10-30 中国药科大学 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂
EP4523755A3 (en) * 2018-09-18 2025-06-11 F. Hoffmann-La Roche AG Quinazoline derivatives as antitumor agents
CN109734674B (zh) * 2019-02-26 2022-08-26 中国药科大学 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途
TWI899080B (zh) * 2019-05-27 2025-10-01 大陸商迪哲（江蘇）醫藥股份有限公司 Ｄｎａ依賴性蛋白激酶抑制劑

Also Published As

Publication number Publication date
KR20250009417A (ko) 2025-01-17
WO2023177592A1 (en) 2023-09-21
MX2024011346A (es) 2025-01-09
JP2025509830A (ja) 2025-04-11
EP4493184A1 (en) 2025-01-22
EP4493184A4 (en) 2026-03-18
US20230293539A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
USRE49556E1 (en) Compounds and compositions as protein kinase inhibitors
CA3093851A1 (en) Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
EP3677584A1 (en) Compound having bruton's tyrosine kinase (btk)-inhibition and degradation activity
AU2020286339B2 (en) Compositions and methods for inhibiting kinases
FR2943669A1 (fr) Derives de nicotinamide,leur preparation et leur application en therapeutique
US20230293539A1 (en) Mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof
US20210171454A1 (en) hTRPV1 CHEMICAL AGENTS
KR20250023339A (ko) 페닐 트라이아졸 mll1-wdr5 단백질-단백질 상호작용 저해제
JP6795525B2 (ja) 炭酸脱水酵素阻害剤としてのアリールスルホンアミド化合物およびその治療的使用
US20230095530A1 (en) Compound used as ret kinase inhibitor and application thereof
US20230286948A1 (en) Haloalkylpyridyl triazole mll1-wdr5 protein-protein interaction inhibitor
HK1191936A (en) Compounds and compositions as protein kinase inhibitors

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240912

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240920

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240920

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240920

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250225

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250225

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250225

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260313

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260313

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260421